RAGE binds C1q and enhances C1q-mediated phagocytosis

Cellular Immunology

Volumn 274, Issue 1-2, 2012, Pages 72-82

  Ma, Wanchao ^a   Rai, Vivek ^a   Hudson, Barry I ^a   Song, Fei ^a   Schmidt, Ann Marie ^a   Barile, Gaetano R ^a  

^a Columbia University ^*  (United States)

Author keywords

Adhesion molecules; C1q; Complement; Efferocytosis; Macrophages; Monocytes; Phagocytosis; RAGE

Indexed keywords

CD11B ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT RAGE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL ADHESION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; INHIBITION KINETICS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE;

ANTIBODIES, MONOCLONAL; CELL ADHESION; CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; HUMANS; LEUKOCYTES; MACROPHAGE-1 ANTIGEN; MEMBRANE GLYCOPROTEINS; PHAGOCYTOSIS; PROTEIN BINDING; RECEPTORS, COMPLEMENT; RECEPTORS, IMMUNOLOGIC; SEQUENCE ALIGNMENT; U937 CELLS;

EID: 84859896425     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.02.001     Document Type: Article

References (44)

1. Teh B.K., Yeo J.G., Chern L.M., Lu J. C1q regulation of dendritic cell development from monocytes with distinct cytokine production and T cell stimulation. Mol. Immunol. 2011, 48:1128-1138.
2. Paidassi H., Tacnet-Delorme P., Garlatti V., Darnault C., Ghebrehiwet B., Gaboriaud C., Arlaud G.J., Frachet P. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J. Immunol. 2008, 180:2329-2338.
3. Perry V.H., O'Connor V. C1q: the perfect complement for a synaptic feast?. Nat. Rev. 2008, 9:807-811.
4. Stevens B., Allen N.J., Vazquez L.E., Howell G.R., Christopherson K.S., Nouri N., Micheva K.D., Mehalow A.K., Huberman A.D., Stafford B., Sher A., Litke A.M., Lambris J.D., Smith S.J., John S.W., Barres B.A. The classical complement cascade mediates CNS synapse elimination. Cell 2007, 131:1164-1178.
5. Duus K., Hansen E.W., Tacnet P., Frachet P., Arlaud G.J., Thielens N.M., Houen G. Direct interaction between CD91 and C1q. FEBS J. 2010, 277:3526-3537.
6. Zutter M.M., Edelson B.T. The alpha2beta1 integrin: a novel collectin/C1q receptor. Immunobiology 2007, 212:343-353.
7. Ghiran I., Tyagi S.R., Klickstein L.B., Nicholson-Weller A. Expression and function of C1q receptors and C1q binding proteins at the cell surface. Immunobiology 2002, 205:407-420.
8. McGreal E.P., Ikewaki N., Akatsu H., Morgan B.P., Gasque P. Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. J. Immunol. 2002, 168:5222-5232.
9. Ballinger M.L., Thomas M.C., Nigro J., Ivey M.E., Dilley R.J., Little P.J. Glycated and carboxy-methylated proteins do not directly activate human vascular smooth muscle cells. Kidney Int. 2005, 68:2756-2765.
10. Ferhani N., Letuve S., Kozhich A., Thibaudeau O., Grandsaigne M., Maret M., Dombret M.C., Sims G.P., Kolbeck R., Coyle A.J., Aubier M., Pretolani M. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010, 181:917-927.
11. Zeng S., Dun H., Ippagunta N., Rosario R., Zhang Q.Y., Lefkowitch J., Yan S.F., Schmidt A.M., Emond J.C. Receptor for advanced glycation end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia/reperfusion injury. J. Hepatol. 2009, 50:929-936.
12. Manfredi A.A., Capobianco A., Esposito A., De Cobelli F., Canu T., Monno A., Raucci A., Sanvito F., Doglioni C., Nawroth P.P., Bierhaus A., Bianchi M.E., Rovere-Querini P., Del Maschio A. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J. Immunol. 2008, 180:2270-2275.
13. Yang D., Chen Q., Yang H., Tracey K.J., Bustin M., Oppenheim J.J. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukoc. Biol. 2007, 81:59-66.
14. Chen Y., Akirav E.M., Chen W., Henegariu O., Moser B., Desai D., Shen J.M., Webster J.C., Andrews R.C., Mjalli A.M., Rothlein R., Schmidt A.M., Clynes R., Herold K.C. RAGE ligation affects T cell activation and controls T cell differentiation. J. Immunol. 2008, 181:4272-4278.
15. Moser B., Szabolcs M.J., Ankersmit H.J., Lu Y., Qu W., Weinberg A., Herold K.C., Schmidt A.M. Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation. Am. J. Transplant. 2007, 7:293-302.
16. Kokkola R., Andersson A., Mullins G., Ostberg T., Treutiger C.J., Arnold B., Nawroth P., Andersson U., Harris R.A., Harris H.E. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand. J. Immunol. 2005, 61:1-9.
17. Liliensiek B., Weigand M.A., Bierhaus A., Nicklas W., Kasper M., Hofer S., Plachky J., Grone H.J., Kurschus F.C., Schmidt A.M., Yan S.D., Martin E., Schleicher E., Stern D.M., Hammerling G.G., Nawroth P.P., Arnold B. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 2004, 113:1641-1650.
18. Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., Susarla S.M., Ulloa L., Wang H., DiRaimo R., Czura C.J., Wang H., Roth J., Warren H.S., Fink M.P., Fenton M.J., Andersson U., Tracey K.J. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:296-301.
19. Ruan B.H., Li X., Winkler A.R., Cunningham K.M., Kuai J., Greco R.M., Nocka K.H., Fitz L.J., Wright J.F., Pittman D.D., Tan X.Y., Paulsen J.E., Lin L.L., Winkler D.G. Complement C3a, CpG oligos, and DNA/C3a complex stimulate IFN-alpha production in a receptor for advanced glycation end product-dependent manner. J. Immunol. 2010, 185:4213-4222.
20. Friggeri A., Banerjee S., Biswas S., de Freitas A., Liu G., Bierhaus A., Abraham E. Participation of the receptor for advanced glycation end products in efferocytosis. J. Immunol. 2011, 186:6191-6198.
21. He M., Kubo H., Morimoto K., Fujino N., Suzuki T., Takahasi T., Yamada M., Yamaya M., Maekawa T., Yamamoto Y., Yamamoto H. Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Rep. 2011, 12:358-364.
22. Park L., Raman K.G., Lee K.J., Lu Y., Ferran L.J., Chow W.S., Stern D., Schmidt A.M. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 1998, 4:1025-1031.
23. Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., Nagashima M., Lundh E.R., Vijay S., Nitecki D., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 1995, 270:25752-25761.
24. Reiniger N., Lau K., McCalla D., Eby B., Cheng B., Lu Y., Qu W., Quadri N., Ananthakrishnan R., Furmansky M., Rosario R., Song F., Rai V., Weinberg A., Friedman R., Ramasamy R., D'Agati V., Schmidt A.M. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 2010, 59:2043-2054.
25. Barile G.R., Pachydaki S.I., Tari S.R., Lee S.E., Donmoyer C.M., Ma W., Rong L.L., Buciarelli L.G., Wendt T., Horig H., Hudson B.I., Qu W., Weinberg A.D., Yan S.F., Schmidt A.M. The RAGE axis in early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2005, 46:2916-2924.
26. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M.A., Kislinger T., Ingram M., Lu A., Tanaka H., Hori O., Ogawa S., Stern D.M., Schmidt A.M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360.
27. Defacque H., Piquemal D., Basset A., Marti J., Commes T. Transforming growth factor-beta1 is an autocrine mediator of U937 cell growth arrest and differentiation induced by vitamin D3 and retinoids. J. Cell. Physiol. 1999, 178:109-119.
28. Gingras M.C., Margolin J.F. Differential expression of multiple unexpected genes during U937 cell and macrophage differentiation detected by suppressive subtractive hybridization. Exp. Hematol. 2000, 28:65-76.
29. Duncan A.R., Winter G. The binding site for C1q on IgG. Nature 1988, 332:738-740.
30. Gaboriaud C., Juanhuix J., Gruez A., Lacroix M., Darnault C., Pignol D., Verger D., Fontecilla-Camps J.C., Arlaud G.J. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J. Biol. Chem. 2003, 278:46974-46982.
31. Idusogie E.E., Presta L.G., Gazzano-Santoro H., Totpal K., Wong P.Y., Ultsch M., Meng Y.G., Mulkerrin M.G. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 2000, 164:4178-4184.
32. Kaul M., Loos M. Dissection of C1q capability of interacting with IgG. Time-dependent formation of a tight and only partly reversible association. J. Biol. Chem. 1997, 272:33234-33244.
33. Xie J., Burz D.S., He W., Bronstein I.B., Lednev I., Shekhtman A. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J. Biol. Chem. 2007, 282:4218-4231.
34. Lauvrak V., Brekke O.H., Ihle O., Lindqvist B.H. Identification and characterisation of C1q-binding phage displayed peptides. Biol. Chem. 1997, 378:1509-1519.
35. Goodman E.B., Anderson D.C., Tenner A.J. C1q triggers neutrophil superoxide production by a unique CD18-dependent mechanism. J. Leukoc. Biol. 1995, 58:168-176.
36. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 1992, 267:14998-15004.
37. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
38. Orlova V.V., Choi E.Y., Xie C., Chavakis E., Bierhaus A., Ihanus E., Ballantyne C.M., Gahmberg C.G., Bianchi M.E., Nawroth P.P., Chavakis T. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 2007, 26:1129-1139.
39. Banerjee S., Friggeri A., Liu G., Abraham E. The C-terminal acidic tail is responsible for the inhibitory effects of HMGB1 on efferocytosis. J. Leukoc. Biol. 2010, 88:973-979.
40. Nayak A., Ferluga J., Tsolaki A.G., Kishore U. The non-classical functions of the classical complement pathway recognition subcomponent C1q. Immunol. Lett. 2010, 131:139-150.
41. Lu J., Wu X., Teh B.K. The regulatory roles of C1q. Immunobiology 2007, 212:245-252.
42. van Zoelen M.A., Schmidt A.M., Florquin S., Meijers J.C., de Beer R., de Vos A.F., Nawroth P.P., Bierhaus A., van der Poll T. Receptor for advanced glycation end products facilitates host defense during Escherichia coli-induced abdominal sepsis in mice. J. Infect. Dis. 2009, 200:765-773.
43. van Zoelen M.A., Achouiti A., Schmidt A.M., Yang H., Florquin S., Tracey K.J., van der Poll T. Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis. Crit. Care Med. 2010, 38:1414-1422.
44. Kishore U., Ghai R., Greenhough T.J., Shrive A.K., Bonifati D.M., Gadjeva M.G., Waters P., Kojouharova M.S., Chakraborty T., Agrawal A. Structural and functional anatomy of the globular domain of complement protein C1q. Immunol. Lett. 2004, 95:113-128.